clobetasol and Hearing-Loss

clobetasol has been researched along with Hearing-Loss* in 1 studies

Other Studies

1 other study(ies) available for clobetasol and Hearing-Loss

Article	Year
Bone-anchored hearing aid abutment skin overgrowth reduction with clobetasol. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2008, Volume: 139, Issue:6 The bone-anchored hearing aid (BAHA) osseointegrated cochlear stimulator can treat hearing loss in a variety of clinical situations. Occasionally skin/scar overgrowth may cover the abutment. This overgrowth interferes with affixing the BAHA to the abutment. Surgical scar revision/excision has been used to treat this problem. Clobetasol (0.05%), a steroid gel, can reduce skin overgrowth. Experience with skin overgrowth and the efficacy of clobetasol to treat this problem was reviewed.. The authors conducted a retrospective analysis of patients who underwent BAHA abutment implantation from January 2003 through December 2006.. Eighty-eight patients (2 patients received bilateral BAHAs) were reviewed. Twenty (22%) of 90 sites developed overgrowth. Thirteen of 20 sites were treated with clobetasol. The overgrowth resolved in 11 (85%) of 13 sites after treatment. Patients with incomplete skin graft survival were significantly more likely to develop skin overgrowth (P = 0.0017).. Clobetasol is an effective treatment for abutment skin/scar overgrowth. Clobetasol allows patients to resume BAHA use and obviates the need for scar revision. Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cicatrix; Clobetasol; Female; Gels; Glucocorticoids; Hearing Aids; Hearing Loss; Humans; Male; Mastoid; Middle Aged; Retrospective Studies; Treatment Outcome	2008

Article

Year

Bone-anchored hearing aid abutment skin overgrowth reduction with clobetasol.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2008, Volume: 139, Issue:6

The bone-anchored hearing aid (BAHA) osseointegrated cochlear stimulator can treat hearing loss in a variety of clinical situations. Occasionally skin/scar overgrowth may cover the abutment. This overgrowth interferes with affixing the BAHA to the abutment. Surgical scar revision/excision has been used to treat this problem. Clobetasol (0.05%), a steroid gel, can reduce skin overgrowth. Experience with skin overgrowth and the efficacy of clobetasol to treat this problem was reviewed.. The authors conducted a retrospective analysis of patients who underwent BAHA abutment implantation from January 2003 through December 2006.. Eighty-eight patients (2 patients received bilateral BAHAs) were reviewed. Twenty (22%) of 90 sites developed overgrowth. Thirteen of 20 sites were treated with clobetasol. The overgrowth resolved in 11 (85%) of 13 sites after treatment. Patients with incomplete skin graft survival were significantly more likely to develop skin overgrowth (P = 0.0017).. Clobetasol is an effective treatment for abutment skin/scar overgrowth. Clobetasol allows patients to resume BAHA use and obviates the need for scar revision.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cicatrix; Clobetasol; Female; Gels; Glucocorticoids; Hearing Aids; Hearing Loss; Humans; Male; Mastoid; Middle Aged; Retrospective Studies; Treatment Outcome

2008